Empowered Patient Podcast

Karen Jagoda
  • 4.9 (18)
  • Medicine
  • Updated Daily

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

  1. 1d ago ·  Bonus

    Popular Hospital Patient Experience Book Club Builds Empathy and Staff Connections with Dr. Katherine Hockman and Dilshad Marolia NYU Langone Health TRANSCRIPT

    Dr. Katherine Hockman, Director of the Division of Hospital Medicine at NYU Langone Health, and Dilshad Marolia, System Director of Hospitals and Regulatory and Policy Management at NYU Langone Health, are co-leaders of the Patient Experience Book Club for the hospital employees.  Operating since 2012, the program has grown from six books to 12 books per year, with sessions offered in-person and virtually to reach across the entire health system and, in addition, hosts pop-up sessions with visiting authors. The club helps break down departmental silos within the hospital, fostering connections among employees by creating a safe space for intellectual and emotional engagement while helping to combat workplace burnout. Katherine explains, "So my feeling is the Patient Experience Book Club is so much more than just a club where we read books and talk about them. It's really become a community of individuals who get together and share their experience in caring for some of our sickest patients. And it's also become a great venue for the faculty and staff to get to know each other a lot better and to share some of their vulnerabilities. And Dilshad and I, we've really taken it in many, many different directions. So we started off just reading six books a year, and now we're doing 12 books a year and two sessions a month, one in person and one on video for people who are in all parts of our system who can't make it in person."   Dilshad elaborates, "But now also as a community of 53,000 people in our own health system and part of the wider community of New York City and New York State even, how do we view our communities and ourselves, and what books are transforming us, and what are we taking away from each experience? And the level of intellectual engagement is one thing, but there's a high, high level of emotional engagement that I think is rare to find in the workplace to create these safe spaces where you have a vehicle, and I'll use that word, through which you can have a discussion about a very pointed topic beyond, say, an academic journal." #NYULangone #Bookclub #PatientExperience #HumanityinHealthcare #HealthcareLeadership #EmpathyInHealthcare #BurnoutPrevention #HospitalCulture #MedicalHumanities  nyulangonehealth.org Listen to the podcast here

  2. 1d ago

    Popular Hospital Patient Experience Book Club Builds Empathy and Staff Connections with Dr. Katherine Hockman and Dilshad Marolia NYU Langone Health

    Dr. Katherine Hockman, Director of the Division of Hospital Medicine at NYU Langone Health, and Dilshad Marolia, System Director of Hospitals and Regulatory and Policy Management at NYU Langone Health, are co-leaders of the Patient Experience Book Club for the hospital employees.  Operating since 2012, the program has grown from six books to 12 books per year, with sessions offered in-person and virtually to reach across the entire health system and, in addition, hosts pop-up sessions with visiting authors. The club helps break down departmental silos within the hospital, fostering connections among employees by creating a safe space for intellectual and emotional engagement while helping to combat workplace burnout. Katherine explains, "So my feeling is the Patient Experience Book Club is so much more than just a club where we read books and talk about them. It's really become a community of individuals who get together and share their experience in caring for some of our sickest patients. And it's also become a great venue for the faculty and staff to get to know each other a lot better and to share some of their vulnerabilities. And Dilshad and I, we've really taken it in many, many different directions. So we started off just reading six books a year, and now we're doing 12 books a year and two sessions a month, one in person and one on video for people who are in all parts of our system who can't make it in person."   Dilshad elaborates, "But now also as a community of 53,000 people in our own health system and part of the wider community of New York City and New York State even, how do we view our communities and ourselves, and what books are transforming us, and what are we taking away from each experience? And the level of intellectual engagement is one thing, but there's a high, high level of emotional engagement that I think is rare to find in the workplace to create these safe spaces where you have a vehicle, and I'll use that word, through which you can have a discussion about a very pointed topic beyond, say, an academic journal." #NYULangone #Bookclub #PatientExperience #HumanityinHealthcare #HealthcareLeadership #EmpathyInHealthcare #BurnoutPrevention #HospitalCulture #MedicalHumanities nyulangonehealth.org Download the transcript here

  3. 1d ago ·  Bonus

    Ambient AI Transforming Operating Room Utilization Reducing Friction and Boosting Efficiency with David Schummers Apella TRANSCRIPT

    David Schummers, CEO of Apella, uses ambient AI technology, primarily audio- and video-based computer vision, to collect accurate operational data in real time to improve hospital management.  With a key emphasis on operating room scheduling and resource management, this solution replaces manually entered data, which is often inaccurate and entered into the system late. The Apella platform helps hospitals optimize existing OR capacity and efficiency, reduces errors and documentation burden on nurses, provides accurate live operational information, and delivers economic benefits.   David explains, "Apella is focused on using modern technologies to improve the operations of the hospital. If you consider the contribution of hospital operations to our overall healthcare spending, it's about a third of every dollar spent in healthcare is spent on running hospitals, which is a pretty significant contribution. And depending where you were, unfortunately, a lot of that expense is wasted."  "So Apella has built a system for ambient detection that is able to improve the throughput of hospitals and improve the efficiency of hospitals. So that's what we're focused on. The product that we're working on right now is focused on the operating room, which is the largest revenue and expense driver of those health systems that we just talked about."   "So operating rooms are scheduled and managed using data that is entered into the electronic health record. And so the electronic health record was designed to capture all of the patient records and make them available and interoperable. It really wasn't designed as an operational system. As a result, the captured data is limited in several ways. The first way is that it is not always accurate because it's manually entered. What we've found is that about 5% of manually entered data points relate to the scheduling of surgeries and other procedures."  #Apella #HealthcareInnovation #OperatingRoom #AmbientAI #Perioperative #HospitalOperations #Nursing #DigitalHealth #EmpoweredPatient #AmbientAI #ORManagement #OREfficiency #PatientAccess #NursingStaffingCrisis  #HealthcareAI #PerioperativeCare #SurgicalInnovation #OROptimization #PatientOutcomes #EmpoweredPatient #NursingStaffingCrisis #HealthcareAI Apella.io Listen to the podcast here

  4. 2d ago ·  Bonus

    New Dual-Action Nitric Oxide Targets Infection and Inflammation in Chronic Respiratory Disease with Nate Stasko Vast Therapeutics TRANSCRIPT

    Nate Stasko, CEO of Vast Therapeutics, is developing a novel nitric oxide-releasing therapy to treat chronic respiratory diseases, particularly fibrosis bronchiectasis, which is frequently misdiagnosed as asthma or COPD. Their lead drug candidate is a dual-mechanism therapy that is delivered to the lungs via a nebulizer to target both infection and inflammation with the potential to eradicate pathogens rather than just suppressing them. This approach, in early trials, is showing excellent tolerability and eliminates the need for chronic antibiotic use, which carries the risks of toxicity and contributes to antibiotic resistance.  Nate explains, "At Vast Therapeutics, our main idea and goal as a company is to come up with better solutions for the 500 million people worldwide who suffer from chronic respiratory disease. And there is a new disease getting a lot of attention that we're targeting with our lead program called bronchiectasis, and it's often been misdiagnosed as asthma or COPD. And now over a million patients in the US are being diagnosed with bronchiectasis. And the whole campaign is to teach physicians and the whole medical community to suspect this disease over some of these other misdiagnosed diseases."  "Traditionally, patients have been managed with either antibiotics to calm down the infection, but you know the problems of chronic antibiotic use- the liver toxicity, kidney toxicity, and hearing loss associated with long-term antibiotic use are just bad for these patients. Not to mention we have the global problem of antibiotic resistance. And so giving a 52-week course of therapy of antibiotics is less than ideal. And then recently, just last year, there's some hope for these patients where there was a new drug approved called brensocatib, which was the first drug ever approved for bronchiectasis by the FDA. And so now it targets the inflammation." "Having the ability to target two mechanisms of action would be the best therapy. And that's actually what Vast is developing. We're using the body's own ability to make and produce nitric oxide, which is a miracle molecule. And we're delivering nitric oxide back to these patients to target both the infection and inflammation at the same time and improve the overall standard of care for these patients."  #VastTherapeutics #Bronchiectasis #Pulmonology #NitricOxide #RespiratoryMedicine #AntimicrobialResistance #ALX1#ChronicLungDisease #HealthcareInnovation #ClinicalTrials vasttherapeutics.com Listen to the podcast here

  5. 2d ago

    New Dual-Action Nitric Oxide Targets Infection and Inflammation in Chronic Respiratory Disease with Nate Stasko Vast Therapeutics

    Nate Stasko, CEO of Vast Therapeutics, is developing a novel nitric oxide-releasing therapy to treat chronic respiratory diseases, particularly fibrosis bronchiectasis, which is frequently misdiagnosed as asthma or COPD. Their lead drug candidate is a dual-mechanism therapy that is delivered to the lungs via a nebulizer to target both infection and inflammation with the potential to eradicate pathogens rather than just suppressing them. This approach, in early trials, is showing excellent tolerability and eliminates the need for chronic antibiotic use, which carries the risks of toxicity and contributes to antibiotic resistance.  Nate explains, "At Vast Therapeutics, our main idea and goal as a company is to come up with better solutions for the 500 million people worldwide who suffer from chronic respiratory disease. And there is a new disease getting a lot of attention that we're targeting with our lead program called bronchiectasis, and it's often been misdiagnosed as asthma or COPD. And now over a million patients in the US are being diagnosed with bronchiectasis. And the whole campaign is to teach physicians and the whole medical community to suspect this disease over some of these other misdiagnosed diseases."  "Traditionally, patients have been managed with either antibiotics to calm down the infection, but you know the problems of chronic antibiotic use- the liver toxicity, kidney toxicity, and hearing loss associated with long-term antibiotic use are just bad for these patients. Not to mention we have the global problem of antibiotic resistance. And so giving a 52-week course of therapy of antibiotics is less than ideal. And then recently, just last year, there's some hope for these patients where there was a new drug approved called brensocatib, which was the first drug ever approved for bronchiectasis by the FDA. And so now it targets the inflammation." "Having the ability to target two mechanisms of action would be the best therapy. And that's actually what Vast is developing. We're using the body's own ability to make and produce nitric oxide, which is a miracle molecule. And we're delivering nitric oxide back to these patients to target both the infection and inflammation at the same time and improve the overall standard of care for these patients."  #VastTherapeutics #Bronchiectasis #Pulmonology #NitricOxide #RespiratoryMedicine #AntimicrobialResistance #ALX1#ChronicLungDisease #HealthcareInnovation #ClinicalTrials vasttherapeutics.com Download the transcript here

  6. 2d ago ·  Bonus

    Developing Freeze-Dried Blood to Transform Trauma Care with Dr. Scott Walter Defense Health Agency TRANSCRIPT

    Dr. Scott Walter is Director of Technology Transfer and Transition for the 59th Medical Wing of the Defense Health Agency located in San Antonio, Texas. The development of freeze-dried blood is a ground-breaking technology aimed at enabling medics to administer lifesaving blood transfusions at the point of injury. Scott highlights the logistical challenges of current blood products such as short shelf life, blood matching, and the need for cold storage, which this new technology would overcome. One of his current missions is to launch a prize competition to accelerate research, development, and commercialization of this technology, shifting the financial risk from the government to industry and expanding the uses of this product to dramatically improve survival rates and reduce long-term complications.   Scott explains, "Donated blood is very perishable lasting only about six weeks from the date of collection, and it must be maintained just above freezing until it's needed. And then it has to be warmed to body temperature before it can be infused. That makes it really difficult to impossible for medics to carry blood products with them when they're treating patients in remote austere locations like battlefields, for example."   "Well, the key is that freeze-drying enables the donated blood components to be collected, stored, and stockpiled for years after collection. The freeze-dried blood products can be carried by EMS units and medics. Then, once reconstituted, it can be given anywhere without the need for refrigeration." #TraumaCare #EmergencyMedicine #PrehospitalCare #CriticalCare #TransfusionMedicine #MilitaryMedicine #Innovation #FreezeDriedBlood #PatientOutcomes #GlobalHealth DISCLAIMER: The views expressed in this podcast transcript are those of the author and do not necessarily reflect the official policy or position of the Defense Health Agency, Department of War, nor the U.S. Government. Find out more about the prize competition Listen to the podcast here

  7. 2d ago

    Developing Freeze-Dried Blood to Transform Trauma Care with Dr. Scott Walter Defense Health Agency

    Dr. Scott Walter is Director of Technology Transfer and Transition for the 59th Medical Wing of the Defense Health Agency located in San Antonio, Texas. The development of freeze-dried blood is a ground-breaking technology aimed at enabling medics to administer lifesaving blood transfusions at the point of injury. Scott highlights the logistical challenges of current blood products such as short shelf life, blood matching, and the need for cold storage, which this new technology would overcome. One of his current missions is to launch a prize competition to accelerate research, development, and commercialization of this technology, shifting the financial risk from the government to industry and expanding the uses of this product to dramatically improve survival rates and reduce long-term complications.   Scott explains, "Donated blood is very perishable lasting only about six weeks from the date of collection, and it must be maintained just above freezing until it's needed. And then it has to be warmed to body temperature before it can be infused. That makes it really difficult to impossible for medics to carry blood products with them when they're treating patients in remote austere locations like battlefields, for example."   "Well, the key is that freeze-drying enables the donated blood components to be collected, stored, and stockpiled for years after collection. The freeze-dried blood products can be carried by EMS units and medics. Then, once reconstituted, it can be given anywhere without the need for refrigeration." #TraumaCare #EmergencyMedicine #PrehospitalCare #CriticalCare #TransfusionMedicine #MilitaryMedicine #Innovation #FreezeDriedBlood #PatientOutcomes #GlobalHealth DISCLAIMER: The views expressed in this podcast transcript are those of the author and do not necessarily reflect the official policy or position of the Defense Health Agency, Department of War, nor the U.S. Government. Find out more about the competition Download the transcript here

  8. 3d ago ·  Bonus

    Prenatal Gene Therapy for Sickle Cell Disease with Dr. Panicos Shangaris King's College London TRANSCRIPT

    Dr. Panicos Shangaris is from King's College London, where he is a senior clinical lecturer and consultant in maternal and fetal medicine.  He discusses the treatment options for sickle cell disease, an inherited blood condition, and his work on the Pericles project, which aims to treat it before birth. In-utero gene therapy offers a third option for parents of an affected fetus alongside postnatal treatment or pregnancy termination. Panicos emphasizes key advantages of fetal therapy within the first 16 weeks of gestation, the need to address ethical concerns, and ensuring the safety of both the mother and fetus during the procedure.  Panicos explains, "So sickle cell disease is an inherited condition that affects the blood and the molecule in the red cell, which is basically the red blood cell that carries oxygen. So what happens is the red cell has a biconcave shape, and for people who have sickle cell disease, that biconcave shape is lost, and the erythrocyte red cells are sickle-shaped. So because of that, the sickle-shaped red cells have difficulty going through small capillaries and small vessels. They can cause strokes, they can cause pain because they block the blood flow to the small capillaries." "Yes, so the cause is because of an abnormal gene, which basically makes the hemoglobin, the molecule that carries oxygen around the different organs and around the body, instead of there being a problem in the genetic code, if I can put it like that. And that's why the erythrocyte, the red cells, have an abnormal shape. Very well-known what's causing it: a genetic problem." "So Pericles stands for prenatal therapy for Sickle Cell Disease. And what we are trying to achieve is to offer a third option to people who might carry a fetus affected by sickle cell disease. At the moment, the two options are stopping the pregnancy, termination of pregnancy, or having an affected fetus and an unaffected baby and sick postnatal care. So our aim is to offer a third option, which is correcting the disease inside the womb so that the parents have a healthy baby. So correct the gene while the baby is inside the womb. And this is the main aim of the project." #KingsCollegeLondon #KCLResearch #GeneTherapy #PrenatalCare #Hematology #Genomics #EmpoweredPatient #PERICLES #SickleCellDisease #SickleCellAwareness #PreconceptionCare #BeforePregnancy #PregnancyPlanning #CarrierScreening #GeneticCounselling #ReproductiveChoices #PrenatalDiagnosis #PrenatalTherapy #InUteroTherapy #GeneEditing #StemCellTherapy #FetalMedicine #MaternalFetalMedicine #HighRiskPregnancy #IVFJourney #PGTM #PatientVoice #PatientEmpowerment #SharedDecisionMaking #HealthEquity #PrecisionMedicine #PersonalisedMedicine #FutureOfMedicine  kcl.ac.uk Listen to the podcast here

See All (2K)

4.9
out of 5
18 Ratings

About

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

Information